This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
” Experts told STAT there’s been a surge of interest for these compounds from biotech and pharma in the last few months, spurred on most by the presentation of promising clinical data from Summit Therapeutics.
In a recent GlobalDatas survey, The State of the Biopharmaceutical Industry 2025, the largest proportion (41 per cent) of surveyed pharmaceutical industry professionals indicated that the immuno-oncology/ cancer therapeutics present the strongest innovation pipeline in the next five years.
I neglected to have my first child vaccinated against chickenpox; the scars are still present. I offered vaccines to my patients and was adherent to the routine schedules, but certainly did not go out of my way to encourage or cajole. Twenty-five years ago this week, however, I attended the 2000 CDC Measles Elimination Meeting in Atlanta.
While the weight gain was significant, experts at the time said the study’s secondary endpoints, including patient-reported outcomes and physical activity measured by a wearable, presented a more nuanced portrait of how the treatment was influencing patients.
For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place where researchers have developed new therapies in-house and published high-impact papers.
Worried about your health? You can now avail yourself of noninvasive diagnostics that claim to screen for rare birth defects, cancer-associated mutations, and even Alzheimer’s.
But in a clinical trial presented last year , 14 out of 50 patients with relapsed disease saw their tumors shrink. It responds poorly to chemotherapy and is usually driven by a mutation that can’t be drugged with traditional approaches. Median survival is generally cited as less than a year.
Presently, Tang, via his hedge fund Tang Capital Partners and his privately held shell company, Concentra Biosciences, has a $3-per-share cash offer on the table to acquire and shut down Acelyrin, the distressed, cash-rich biotech that is seeking a second life as a merger partner with another troubled biotech.
Hundreds of messages from an internal chat board for an international group of transgender health professionals were leaked in a think tank report last week and framed as revealing serious health risks associated with gender-affirming care, including cancer.
Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug developer.
De-Shaine Murray is working at the cutting edge of neurotechnology. As a postdoctoral fellow at Yale, he is developing a device to monitor the brain following traumatic brain injury or stroke. He is also trying to fight the long legacy of racism in neuroscience.
Then, at the American Association for Cancer Research annual meeting in 2023, the late New York University immunologist Jeffrey Weber presented a Phase 2 clinical trial on a personalized cancer vaccine for melanoma developed by Moderna and Merck. That “lit the field on fire,” said Sullivan, who was involved with the research.
Others that no longer appear on the final list of presenters: pharmacy chain Walgreens, medical device maker BD, insurer Oscar Health, physician practice management firm Agilon Health, medical device maker Inari Medical, biotech firm Applied Therapeutics, post-acute provider PACS, biotech firm IGM, and U.S. Morgan circulated on Dec.
Federal health officials wrestling with when and how to use artificial intelligence will on Wednesday host an invitation-only meeting of AI leaders across industry, academia, and government. Called “AI in Action: Transforming Health and Human Services,” the three-hour event is hosted by the federal health department.
CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting.
DENVER — The GLP-1 medication liraglutide significantly reduced opioid cravings in a small analysis presented on Saturday. It is the first randomized controlled trial to test anti-obesity drugs against opioid addiction, which kills around 80,000 people in the U.S. Read the rest…
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday. The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.
A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler, under-the-skin injection is equally effective as the currently approved intravenous infusion, according to study results presented Wednesday by its maker, Eisai.
CHICAGO — Comfort can be delivered to patients with advanced cancer virtually just as well as in person, according to a new study presented on Sunday at the American Society of Clinical Oncology annual meeting in Chicago.
The occasion: Nvidia, the chipmaker whose market capitalization has soared beyond $1 trillion because of its role in the revolutionary work occurring in artificial intelligence, was presenting at the J.P. ” When Kimberly Powell, Nvidia’s vice president of health care, finished her presentation, the room erupted in applause.
These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark. Continue to STAT+ to read the full story…
In a presentation in London about vaccine development, Berkley, the former CEO of Gavi, the Vaccine Alliance, raised the issue of H5N1 bird flu when discussing whether the world was ready for another pandemic following its experience with Covid-19.
Meeting Monday, the first of two days of presentations, they discussed research findings to inform a report to the Department of Health and Human Services and the Department of Agriculture. The results will be published in December.
NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post-presentation cocktail reception. If the sleep tech magnate could have used more shuteye, he didn’t show it.
MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting , a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.
At the recent annual International AIDS Conference, a startling presentation about the newest wonder drug in HIV prevention brought a raucous standing ovation. Lenacapavir, a novel drug given as an injection under the skin every six months, was 100% successful in preventing HIV in adolescent girls and young women in two countries in Africa.
Let’s set the table for Sunday’s presentation of the lung cancer immunotherapy trial known as HARMONi-2. Sunday’s HARMONi-2 presentation at the World Conference on Lung Cancer should provide the answers. Continue to STAT+ to read the full story…
Plus, Jason Mast pops in to give an update on Uniqure’s puzzling approach to presenting trial results. Today, we get into why Amy Abernethy is leaving Verily, and why the ongoing reckoning with AI doesn’t necessarily need the voice of Google to chime in. Read the rest…
The data, presented this week as an abstract at Digestive Disease Week in D.C., But a different medication, one frequently used off-label for the condition, could provide greater benefit to patients with alcohol-associated liver disease, a new study suggests.
The results were released in an abstract at the annual meeting of the European Society of Molecular Oncology, where they will be presented in full on Sunday. Continue to STAT+ to read the full story…
But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3. Continue to STAT+ to read the full story…
Part of it was the patients’ presentations: Some didn’t have the classic symptoms of the condition. LONDON — There was something odd about these Alzheimer’s cases. But it was also that the patients were in their 40s and 50s, even their 30s, far younger than people who normally develop the disease.
A doctor, a patient advocate, and the most powerful figure in the methadone treatment industry presented competing visions for the future of American addiction medicine this week — a conversation that touched on stigma, patients’ rights, and a stark divide in health provider attitudes toward patients with addiction.
Which presentations are worth catching at ASCO this weekend? This week on “The Readout LOUD,” we preview some of the research that will be presented at the American Society of Clinical Oncology conference in Chicago. What is exon-skipping? And how do you pronounce bronchiectasis?
Long Covid — the name adopted for cases of prolonged symptoms after an acute bout of Covid-19 — is an umbrella diagnosis covering a broad range of clinical presentations and abnormal biological processes.
of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver. from the lowest to highest doses. When compared with the 29.7% Continue to STAT+ to read the full story…
That conversation may happen less often if changes in the risk model presented by the American Heart Association in November translate into new guidelines for prescribing statins.
A 30-year-old female with a past medical history of Crohn’s Disease presented to the ED for evaluation of an acutely bruised right 4th finger. She stated she was typing on a computer keyboard approximately 10 minutes prior to presentation and she noticed a sudden popping sensation at the base of her right ring finger.
Somehow, between back-to-back meetings and presentations, I’d have to bust out that abominable contraption and do my thing. But skipping a session ends up being even more painful. Naturally, I expected navigating the J.P. Morgan Healthcare Conference in San Francisco would be more complicated this year.
The results, presented at the European Society of Gene & Cell Therapy meeting in Brussels, are a major step for a technology that could transform treatment of numerous diseases. Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called prime editing to edit liver cells in monkeys.
Six years after the FDA approved Zolgensma, a Novartis gene therapy for spinal muscular atrophy for children under age 2, investigators presented data from a trial in 126 children showing the treatment worked for children between the ages of 2 and 17 , STAT reports. It has been a long wait, although the limitation was logical.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content